40 CROs Select Veeva Vault CTMS to Drive Clinical Trial Operations

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

PLEASANTON, Calif. , Oct. 17, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 40 contract research organizations (CROs) selected Veeva Vault CTMS to deliver faster and more efficient trials to sponsors, which includes four of the top six global CROs. These global leaders – Labcorp Drug Development, Parexel, PPD clinical research business of Thermo Fisher Scientific Inc., and Syneos Health – are unifying clinical on a single platform as they expand their use of Veeva Vault Clinical Suite from Vault eTMF to now include Vault CTMS.

Metadata

Provider:

PR Newswire

Retrieved on:

Monday, October 17, 2022

Information

Tags:

PPD, Syneos Health, Thermo Fisher Scientific, Cros, Form 10-Q, SEC, NYSE, Professional corporation, Mindful Scientific Inc., CTMS, Industry, Clinical trial, Veeva Systems, Fine chemical, Pharmaceutical industry, Parexel, Vault

Geotags:

CALIFORNIA

Stock Symbol:

NYSE:VEEV

Summary

Key Points:

These global leaders Labcorp Drug Development, Parexel, PPD clinical research business of Thermo Fisher Scientific Inc., and Syneos Health are unifying clinical on a single platform as they expand their use of Veeva Vault Clinical Suite from Vault eTMF to now include Vault CTMS.
As CROs increasingly standardize on Vault CTMS, they can support sponsor preference for Veeva Vault while modernizing study operations for more efficient execution.
Vault CTMS provides a complete view of trial metrics so CROs can better manage study performance and increase transparency to sponsors.
"Veeva Vault CTMS is the first clinical trial management application developed to meet the needs of both sponsors and CROs," said Henry Galio, vice president, Veeva Vault CTMS.

40 CROs Select Veeva Vault CTMS to Drive Clinical Trial Operations

Leading CROs unifying trial data and processes for greater visibility and speed

PLEASANTON, Calif. , Oct. 17, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 40 contract research organizations (CROs) selected Veeva Vault CTMS to deliver faster and more efficient trials to sponsors, which includes four of the top six global CROs. These global leaders – Labcorp Drug Development, Parexel, PPD clinical research business of Thermo Fisher Scientific Inc., and Syneos Health – are unifying clinical on a single platform as they expand their use of Veeva Vault Clinical Suite from Vault eTMF to now include Vault CTMS.

Also selected by more than 120 sponsors, including 9 of the top 20 pharmaceutical companies, Vault CTMS has fast become the industry-leading solution for clinical trial management. As CROs increasingly standardize on Vault CTMS, they can support sponsor preference for Veeva Vault while modernizing study operations for more efficient execution.

Vault CTMS provides a complete view of trial metrics so CROs can better manage study performance and increase transparency to sponsors. Sponsors and CROs using Vault CTMS work on a consistent industry standard platform that makes it easier to collaborate and share study information for real-time visibility across the study portfolio.

"Veeva Vault CTMS is the first clinical trial management application developed to meet the needs of both sponsors and CROs," said Henry Galio, vice president, Veeva Vault CTMS. "As more companies advance trial operations with Veeva, sponsors, CROs, and sites can work closer together to drive faster study endpoints and accelerate subject enrollment in trials."

Vault CTMS is part of the Veeva Vault Clinical Operations Suite, enabling companies to share information and documents across eTMF, CTMS, payments, study start-up, and study training for better collaboration and execution throughout the study lifecycle.

Additional Information
For more on Veeva Vault CTMS, visit: veeva.com/CTMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find here (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:
Deivis Mercado
Veeva Systems
925-226-8821
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/40-cros-select-veeva-vault-ctms-to-drive-clinical-trial-operations-301650493.html

SOURCE Veeva Systems